Zacks' 7 Best Stocks for June, 2013
FREE Report for Zacks.com
Visitors Only

They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.

Today, you can see them free.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 06/18/2013

Company Name Symbol %Change
STAAR SURGIC STAA
10.98%
DTS INC DTSI
6.89%
ANIKA THERAP ANIK
6.04%
LUMOS NETWOR LMOS
5.70%
INSTEEL IND IIIN
5.28%

UCB-Immunomedics Restructure Deal

by Zacks Equity Research

January 05, 2012 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

UCB (UCBJF) and Immunomedics, Inc. (IMMU - Snapshot Report) recently announced that they have amended their agreement for the worldwide development, marketing and sale of epratuzumab for all autoimmune disease indications. According to the new agreement, UCB returned its buy-in right to Immunomedics for the cancer indication of the candidate, and in return got the flexibility to select a partner to sublicense epratuzumab’s rights for certain territories.

On the execution of the amendment, Immunomedics is entitled to receive a cash payment of $30 million. Moreover, if UCB exercises its right to sublicense, it will have to make another cash payment of $30 million to Immunomedics, along with additional payments upon the achievement of new regulatory and sales milestones. Also as a part of the agreement, Immunomedics will issue a 5-year warrant to UCB for the purchase of one million shares of Immunomedics’ common stock at an exercise price of $8.00 per share.

UCB in-licensed epratuzumab from Immunomedics in May 2006, to develop, market and sell the molecule worldwide as a treatment for autoimmune diseases. Under the original agreement UCB was to book potential future sales of epratuzumab and pay royalties on these sales to Immunomedics.

We note that epratuzumab is currently being evaluated in two late-stage trials, EMBODY1 and EMBODY 2, for the treatment of patients with moderate-to-severe lupus. Both these trials are being conducted to evaluate the efficacy, safety, tolerability, and immunogenicity of epratuzumab when administered with standard-of-care treatments in patients with moderate-to-severe systemic lupus erythematosus (SLE). Initial results from these trials are expected in the first half of 2014.

We currently have a Zacks #3 Rank (short-term Hold rating) on UCB.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.